A significant new Cochrane review has delivered a stark warning to the medical community: the widespread off-label use of ketamine to treat chronic pain lacks robust scientific support. The comprehensive analysis, conducted by researchers from UNSW Sydney, Neuroscience Research Australia (NeuRA), and Brunel University of London, examined 67 trials involving over 2,300 adult participants and found no clear benefits for chronic pain sufferers.

The Growing Concern Over Unproven Treatments

Ketamine, primarily known as an anaesthetic for procedural sedation and short-term pain relief, has increasingly been prescribed off-label to manage chronic pain conditions such as nerve pain, fibromyalgia, and complex regional pain syndrome. This practice has grown substantially despite questions about the underlying evidence base and patient safety concerns.

The new research represents the most comprehensive evaluation to date, examining not only ketamine but four other NMDA receptor antagonists: memantine, dextromethorphan, amantadine, and magnesium. These drugs theoretically reduce pain by blocking specific brain receptors involved in pain signalling, but the review found this promise unfulfilled in clinical practice.

Serious Side Effects Outweigh Uncertain Benefits

Findings from the review reveal troubling patterns in current practice. Participants experienced significant adverse effects including delusions, delirium, paranoia, nausea, and vomiting. These psychotomimetic effects proved particularly distressing for patients, with intravenous use presenting the greatest risks.

“The most common adverse events we saw were psychotomimetic effects such as delusions, delirium and paranoia, as well as nausea and vomiting,” explained Michael Ferraro, Doctoral Candidate at UNSW and NeuRA, who served as the review’s first author. “These effects are distressing for many patients. Clinicians often try to balance the dose for pain relief without triggering those symptoms, but this isn’t always achieved.”

The Evidence Quality Problem

The research team rated the available evidence as low to very low certainty, citing small study sizes and poor methodological quality as primary concerns. This assessment raises serious questions about the research foundation underlying current prescribing practices.

Researchers examined effects across various chronic pain conditions and dosing strategies but discovered no clear evidence of benefit in any specific condition or dose. The systematic approach of the Cochrane review methodology makes these findings particularly significant, as Cochrane reviews represent the gold standard in evidence-based medicine.

Critical Gaps in Research

Perhaps most concerning, the review identified complete gaps in research regarding two crucial outcomes: whether ketamine reduces depressive symptoms or opioid use. This absence is particularly notable because ketamine is frequently proposed for patients with depressive symptoms or those who have developed opioid tolerance.

The findings raise important questions about whether treatment decisions are being made with sufficient supporting data.

“We want to be clear – we’re not saying ketamine is ineffective, but there’s a lot of uncertainty,” Ferraro emphasised. “The data could point to a benefit or no effect at all. Right now, we just don’t know.”

International Implications for Medical Practice

The implications extend far beyond academic interest. Professor Neil O’Connell from Brunel University of London, co-senior author of the review, highlighted the global scope of the problem: “This group of drugs, and ketamine in particular, are in relatively common use for chronic pain around the world. Yet we have no convincing evidence that they are delivering meaningful benefits for people with pain, even in the short term.”

This assessment challenges current medical practice across multiple healthcare systems, where clinicians have increasingly turned to ketamine as conventional pain treatments prove inadequate or carry their own risks.

Lessons from the Opioid Crisis

The researchers drew explicit parallels between current ketamine prescribing patterns and the historical development of the opioid crisis. Professor James McAuley from UNSW and NeuRA warned: “We’ve seen the harm that can come from taking medicines developed for acute pain and applying them to chronic pain, opioids are a prime example. Now we’re seeing a similar pattern with ketamine.”

This comparison carries particular weight given the ongoing struggles with opioid dependence and the urgent need for safe, effective chronic pain treatments. The research suggests that the medical community may be repeating past mistakes by embracing new treatments without adequate evidence.

The Rush to Find Alternatives

As healthcare systems worldwide grapple with reducing opioid prescribing, pressure mounts to identify effective alternatives for chronic pain management. However, the review suggests this search for alternatives may be leading to premature adoption of unproven treatments.

“As opioid prescribing is slowly reduced, there’s a growing demand for alternatives, but we need to be careful not to rush into widespread use without strong evidence,” McAuley cautioned. This measured approach reflects growing awareness that well-intentioned treatment decisions can have unintended consequences when evidence remains insufficient.

Clinical Decision-Making Under Uncertainty

The review’s authors hope their findings will inform both patients and clinicians weighing potential benefits against established harms. The research highlights fundamental questions about medical decision-making when facing uncertain evidence and patient suffering.

Clinical practice often requires decisions despite imperfect information, but the current evidence falls below acceptable thresholds for widespread implementation. The documented side effects, combined with unclear benefits, present an unfavourable risk-benefit profile for patients considering this treatment option.

The Need for High-Quality Trials

The researchers emphasised that their findings should not end the conversation about ketamine’s potential role in chronic pain management but rather redirect it towards more rigorous investigation. “That seems a good reason to be cautious in the clinic and clearly indicates an urgent need to undertake high quality trials,” O’Connell stated.

This call for better research reflects broader challenges in chronic pain treatment, where patient desperation and clinical pressure often outpace scientific validation. The complexity of chronic pain conditions makes research challenging, but the stakes for patients demand higher standards.

Protecting Vulnerable Patients

The findings carry particular significance for vulnerable patient populations who may be most susceptible to treatments with uncertain benefits. Chronic pain patients often exhaust conventional treatment options and may be willing to accept significant risks for potential relief.

The ketamine chronic pain evidence review suggests these patients deserve better protection through rigorous research standards before widespread clinical adoption. The documented psychological side effects raise particular concerns about patient wellbeing and treatment consent processes.

Moving Forward Responsibly

The research team’s measured conclusions reflect the complex balance between acknowledging treatment uncertainty and maintaining hope for chronic pain sufferers. Their work demonstrates the importance of evidence-based medicine in protecting patients from well-intentioned but potentially harmful interventions.

The review’s impact may extend beyond ketamine to influence broader discussions about off-label prescribing, evidence standards, and the pace of medical innovation. As healthcare systems continue seeking effective chronic pain treatments, this research provides crucial guidance about maintaining scientific rigour whilst addressing patient needs.

The comprehensive nature of this Cochrane review makes it a landmark contribution to chronic pain research, offering both caution and direction for future investigations into NMDA receptor antagonists and chronic pain management.

Source: dbrecoveryresources